Cargando…

The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma

The study aims to investigate second primary malignancy (SPM) development and frailty in Turkish geriatric patients with multiple myeloma (MM) and to assess the relationship between overall survival (OS) and various characteristics including SPM and frailty. Seventy-two patients diagnosed with and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ipek, Yildiz, Karademir, Nevra, Yilmazer, Onur, Yilmaz, Guven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297070/
https://www.ncbi.nlm.nih.gov/pubmed/37366906
http://dx.doi.org/10.3390/curroncol30060423
_version_ 1785063796456292352
author Ipek, Yildiz
Karademir, Nevra
Yilmazer, Onur
Yilmaz, Guven
author_facet Ipek, Yildiz
Karademir, Nevra
Yilmazer, Onur
Yilmaz, Guven
author_sort Ipek, Yildiz
collection PubMed
description The study aims to investigate second primary malignancy (SPM) development and frailty in Turkish geriatric patients with multiple myeloma (MM) and to assess the relationship between overall survival (OS) and various characteristics including SPM and frailty. Seventy-two patients diagnosed with and treated for MM were enrolled in the study. Frailty was determined by the IMWG Frailty Score. Fifty-three participants (73.6%) were found to have clinically-relevant frailty. Seven patients (9.7%) had SPM. Median follow-up was 36.5 (22–48.5) months, and 17 patients died during the follow-up period. Overall (OS) was 49.40 (45.01–53.80) months. Shorter OS was found in patients with SPM (35.29 (19.66–50.91) months) compared to those without (51.05 (46.7–55.4) months) (Kaplan–Meier; p = 0.018). The multivariate cox proportional hazards model revealed that patients with SPM had 4.420-fold higher risk of death than those without (HR: 4.420, 95% CI: 1.371–14.246, p = 0.013). Higher ALT levels were also independently associated with mortality (p = 0.038). The prevalence of SPM and frailty was high in elderly patients with MM in our study. The development of SPM independently reduces survival in MM; however, frailty was not found to be independently associated with survival. Our results suggest the importance of individualized approaches in the management of patients with MM, particularly with regard to SPM development.
format Online
Article
Text
id pubmed-10297070
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102970702023-06-28 The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma Ipek, Yildiz Karademir, Nevra Yilmazer, Onur Yilmaz, Guven Curr Oncol Article The study aims to investigate second primary malignancy (SPM) development and frailty in Turkish geriatric patients with multiple myeloma (MM) and to assess the relationship between overall survival (OS) and various characteristics including SPM and frailty. Seventy-two patients diagnosed with and treated for MM were enrolled in the study. Frailty was determined by the IMWG Frailty Score. Fifty-three participants (73.6%) were found to have clinically-relevant frailty. Seven patients (9.7%) had SPM. Median follow-up was 36.5 (22–48.5) months, and 17 patients died during the follow-up period. Overall (OS) was 49.40 (45.01–53.80) months. Shorter OS was found in patients with SPM (35.29 (19.66–50.91) months) compared to those without (51.05 (46.7–55.4) months) (Kaplan–Meier; p = 0.018). The multivariate cox proportional hazards model revealed that patients with SPM had 4.420-fold higher risk of death than those without (HR: 4.420, 95% CI: 1.371–14.246, p = 0.013). Higher ALT levels were also independently associated with mortality (p = 0.038). The prevalence of SPM and frailty was high in elderly patients with MM in our study. The development of SPM independently reduces survival in MM; however, frailty was not found to be independently associated with survival. Our results suggest the importance of individualized approaches in the management of patients with MM, particularly with regard to SPM development. MDPI 2023-06-09 /pmc/articles/PMC10297070/ /pubmed/37366906 http://dx.doi.org/10.3390/curroncol30060423 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ipek, Yildiz
Karademir, Nevra
Yilmazer, Onur
Yilmaz, Guven
The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
title The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
title_full The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
title_fullStr The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
title_full_unstemmed The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
title_short The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
title_sort effects of second primary malignancies and frailty on overall survival and mortality in geriatric turkish patients with multiple myeloma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297070/
https://www.ncbi.nlm.nih.gov/pubmed/37366906
http://dx.doi.org/10.3390/curroncol30060423
work_keys_str_mv AT ipekyildiz theeffectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma
AT karademirnevra theeffectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma
AT yilmazeronur theeffectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma
AT yilmazguven theeffectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma
AT ipekyildiz effectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma
AT karademirnevra effectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma
AT yilmazeronur effectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma
AT yilmazguven effectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma